Nutra Pharma Corporation (OTCQB: NPHC) is actively pursuing
growth plans that will bolster its core business while expanding its reach into
vital commercial markets. A versatile biotechnology company, Nutra Pharma
markets Nyloxin and Pet Pain-Away (homeopathic drugs that treat
moderate-to-severe chronic pain in humans and pets, respectively) to the
over-the-counter pain management market.
Millions of Americans suffer from persistent pain. From
veterans to active-duty military personnel to civilians, the presence of
chronic pain is a major factor in many lives and so is the search for a lasting
cure. This is where Nutra Pharma comes in.
The company has developed pain-relief solutions that are
both potent and long-lasting. They are non-opiate, non-narcotic and
non-addictive. They are safe for vital organs, such as the stomach, liver and
kidney, and they do not affect cognitive or motor skills unfavorably. By
offering pain-relief solutions that counter the record levels of opioid abuse
evidenced in society, as well as the dangers of abusing acetaminophen and
non-steroidal anti-inflammatory drugs such as ibuprofen, Nutra Pharma is poised
to impact a vast, global market and benefit from the resulting rewards.
With the recent expansion of its key personnel, including
the addition of Tom Northrop as senior commercial development officer, Nutra
Pharma is facing several promising stages of growth. Northrop is a member of
Tri-State Capital Partners, a New York-based management advisory and investment
firm that advises promising enterprises, and his involvement with Nutra Pharma
signals Tri-State’s involvement as well.
Tri-State’s support comes part-and-parcel with management
resources, strategy development and implementation expertise and capital
funding knowledge. With this level of support, Nutra Pharma has the tools that
will allow for its expansion into new markets, including an opportunity to
spearhead novel marketing and promotional activities geared toward the elderly,
aging athletes and healthcare, governmental and military entities. The company
will also have an opening to focus on the completion of its
scientifically-rigorous pain relief trials in multiple locations.
That is only the beginning. With Tri-State’s backing, Nutra
Pharma will also have the resources to accelerate the development of its
prescription drug candidates. Presently, the company is designing and
developing treatments for multiple sclerosis, human immunodeficiency virus and
adrenomyeloneuropath.
For more information on the company, visit www.NutraPharma.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
No comments:
Post a Comment